Teplizumab - MacroGenics

Drug Profile

Teplizumab - MacroGenics

Alternative Names: hOKT3-gamma-1-ala-ala; hOKT3-γ1-ala-ala; MGA031

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tolerance Therapeutics
  • Developer Immune Tolerance Network; MacroGenics; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health (USA)
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Multiple sclerosis; Psoriasis; Psoriatic arthritis

Most Recent Events

  • 08 Sep 2017 Phase-II development for Type-1 diabetes mellitus (Prevention) is ongoing in USA, Canada and Germany (IV)
  • 15 Dec 2016 Biomarkers information updated
  • 11 May 2015 Teplizumab is still in phase II trials for Type-1 diabetes mellitus (Prevention) in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top